Alnylam Pharmaceuticals | ALNY - Vertriebs- Und Verwaltungskosten





Vertriebs- Und Verwaltungskosten Veränderung Datum
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
Amgen USD 1.58B 354M 2026-03
Arrowhead Research USD 41.74M 4.28M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Incyte USD 328.1M 62.31M 2026-03
Ionis Pharmaceuticals USD 151M 21M 2026-03
Moderna USD 173M 135M 2026-03
Neurocrine Biosciences USD 318.5M 16.7M 2026-03
Novartis USD 3.44B 132M 2025-12
PTC Therapeutics USD 73.89M 13.31M 2026-03
Regeneron Pharmaceuticals USD 647.7M 127.3M 2026-03
Sangamo BioSciences USD 9.64M 1.83M 2024-06
Sanofi EUR 2.75B 455M 2025-12
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Takeda JPY 292B 9.21B 2026-03
Tectonic Therapeutic USD 3.44M 1.52M 2025-12
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
Vertex Pharmaceuticals USD 493.7M 6.7M 2026-03
Xencor USD 82.12M 65.08M 2026-03